Huluwa Pharmaceutical Achieves a Strong Start in 2026 R&D: Generic Ebastine Oral Solution Approved, Marking Entry into the Allergy Therapeutics Field

At the beginning of the new year, good news has been coming in succession. Recently, the generic drug independently developed by Hainan Huluwa Pharmaceutical Group, Ebastine Oral Solution, officially obtained a drug registration certificate issued by the National Medical Products Administration (Approval No.: GYZZ YBH00082026).

This marks a major breakthrough for Huluwa Pharmaceutical in the field of allergic disease treatment, achieving a "strong start" in its 2026 scientific innovation efforts and injecting strong momentum into the company's high-quality development in the new year.

I. Dosage Form Advantages: Filling a Market Gap and Benefiting Massive Patients

Ebastine is a highly effective and selective second-generation H1 histamine receptor antagonist, mainly used for the treatment of allergic diseases such as allergic rhinitis and chronic idiopathic urticaria. Compared with tablets or capsules, the oral solution dosage form offers significant advantages, including ease of administration, flexible dosing, rapid onset of action, and better suitability for children, elderly patients, and those with swallowing difficulties.

Currently, ebastine in the domestic market is mainly available in tablet form, while oral solution formulations are relatively scarce. The approval of Huluwa Pharmaceutical's Ebastine Oral Solution effectively fills this dosage form gap in the domestic market, providing a better treatment option for allergy patients, particularly pediatric patients. The launch of this product will help improve the accessibility and convenience of medications for allergic diseases in China, benefiting a wide range of patients.

II. Targeting a Billion-Yuan Market Segment: Strengthening Strategic Presence in the Allergy Therapeutics Field

Allergic rhinitis and urticaria are common chronic diseases worldwide. With environmental changes and increasing life pressures, China has a large and continuously growing patient population. According to data from Menet, China's anti-allergy drug market has maintained steady growth for several consecutive years and is expected to exceed RMB 100 billion by 2026, indicating substantial market potential.

The approval of Ebastine Oral Solution reflects Huluwa Pharmaceutical's strategic positioning based on precise insight into market trends and its deep presence in the high-growth allergy therapeutics sector. This is not only the success of a single product, but also the result of long-term accumulation within the company's R&D pipeline in this therapeutic area. By entering this rapidly growing market, Huluwa Pharmaceutical is expected to quickly build brand influence, capture market share, and develop new growth drivers.

III. Technology-Driven Development: Innovation Leading High-Quality Growth

The approved Ebastine Oral Solution was developed and submitted in strict accordance with the national chemical drug new registration classification requirements, and completed comprehensive pharmaceutical equivalence (PE) and bioequivalence (BE) studies. The study data fully demonstrate that the product is consistent with the reference listed drug in active ingredients, dosage form, route of administration, quality attributes, and bioavailability, achieving therapeutic equivalence. The approval of this product provides further evidence of Huluwa Pharmaceutical's "R&D-driven, innovation-led" strategy. The company has established a provincial-level enterprise technology center and a postdoctoral research workstation, with long-term expertise in pediatric medicines and respiratory therapeutics, supported by a strong R&D and innovation system and a stringent quality management system. This approval once again demonstrates the company's strong technical capability and efficient execution in complex formulation development and consistency evaluation.

IV. Strategic Upgrade: From "Pediatric Medicine Specialist" to "Guardian of Health Across the Entire Life Cycle"

Huluwa Pharmaceutical has long been recognized as a leading enterprise in China's pediatric pharmaceutical sector, with products such as Pediatric Lung-Heat Cough and Asthma Granules widely known in households. The approval of the ebastine oral solution, particularly its application potential in pediatric allergy patients, further consolidates the company's professional strengths in the pediatric medication field. At the same time, as the product is also indicated for adult patients with allergic conditions, it marks a steady strategic transition by Huluwa Pharmaceutical, from a focus on pediatric medicines to a comprehensive pharmaceutical and healthcare enterprise covering the entire population and full life-cycle health needs. This breakthrough in the allergy therapeutic area represents a key step in diversifying the company's product portfolio and expanding its market segments, reflecting its long-term strategic vision and ambition.

V. Looking Ahead: Continuous Innovation in Support of a Healthy China

Liu Jingping, Party Secretary and Chairperson of Huluwa Pharmaceutical Group, stated: "The approval of the Ebastine Oral Solution marks a positive start to 2026 for the Company. We will continue to adhere to a clinical-needs-oriented approach and drive innovation through high-quality R&D. In the future, Huluwa Pharmaceutical will further increase its R&D investment, focusing on core therapeutic areas including respiratory, digestive, anti-infective, and anti-allergic diseases, and will advance the development and commercialization of more high-end generics, innovative drugs, and improved new drugs. This will provide doctors and patients with more and better treatment options and further support the 'Healthy China' initiative through Huluwa Pharmaceutical Group's continued efforts."

With the product about to enter production and market launch, Huluwa Pharmaceutical has completed comprehensive preparations in manufacturing, marketing, and academic promotion. It is expected to be officially available nationwide in the second quarter of 2026, providing a timely treatment option for the allergy season.

Source: Menet Retail Observation

Editor: Huluwa Pharmaceutical Group